Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 05/25 06:02:14 pm
64.684 USD   +0.58%
05/24 GILEAD SCIENCES : Value Trap?
05/19 GILEAD SCIENCES : considers producing Hep C drug in Egypt
05/19 GILEAD SCIENCES : American “Gilead Sciences” considers p..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Gilead Sciences, Inc. : U.S. FDA Grants Priority Review for Truvada? for Reducing the Risk of Acquiring HIV Infection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2012 | 01:38am CEST

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 13, 2012-- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada® (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults. Truvada was approved by the FDA in 2004 for the treatment of HIV-1 infection and is currently the most-prescribed antiretroviral treatment in the United States.

The FDA grants priority review status to drug candidates that provide major advances in treatment or provide a treatment where no adequate therapy exists. Gilead submitted the Truvada for PrEP sNDA on December 15, 2011. The FDA has set a target review date for Truvada for PrEP under the Prescription Drug User Fee Act (PDUFA) of June 15, 2012. The agency has also indicated that Truvada for PrEP will be discussed at the FDA Antiviral Drugs Advisory Committee meeting scheduled in May.

If the sNDA is approved, Truvada would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV. The sNDA is based on the results of two large placebo-controlled trials of Truvada as PrEP sponsored by the U.S. National Institutes of Health and the University of Washington. Several other clinical studies support the use of Truvada for HIV risk reduction.

Truvada is not currently indicated to reduce the risk of HIV infection.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that the FDA may not approve Truvada for HIV-1 risk reduction, and any approval, if granted, may have significant limitations on its use. Additionally, even if approved, physicians may be reluctant to prescribe the product for HIV risk reduction, and payers may be reluctant to approve or provide reimbursement for the product for HIV risk reduction. As a result, there may not be significant use of Truvada as a risk reduction tool. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

U.S. . www.Truvada.com

Truvada is a registered trademark of Gilead Sciences, Inc.

For more information on Gilead Sciences, please visit the company's website at or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936 (Investors)
Cara Miller, 650-522-1616 (Media)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
05/24 GILEAD SCIENCES : Value Trap?
05/19 GILEAD SCIENCES : considers producing Hep C drug in Egypt
05/19 GILEAD SCIENCES : American “Gilead Sciences” considers producing new..
05/18 GILEAD SCIENCES, INC. (NASDAQ : GILD) Files An 8-K Submission of Matters to a Vo..
05/18 GILEAD SCIENCES : Submission of Matters to a Vote of Security Holders (form 8-K/..
05/12 GILEAD SCIENCES,INC. (NASDAQ : GILD) Files An 8-K Departure of Directors or Cert..
05/12 GILEAD SCIENCES INC : Change in Directors or Principal Officers, Submission of M..
05/11 GILEAD SCIENCES : to Present at the Bank of America Merrill Lynch Healthcare Con..
05/10 GILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
05/09 NATCO PHARMA : launches Hepatitis C drug Velpanat in India
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07:32a 14 Stocks For 2017 And Beyond - May Update
05/24 How To Double Your Money On A 6% Up Move In Gilead Sciences
05/24 BBP : A Diversified Biotech ETF
05/24 Gilead's Chinese HCV Revenues - How Much To Expect And When
05/24 The No. 1 Stock In The World (Revisited) - Apple Up, Realty Income Down
Advertisement
Financials ($)
Sales 2017 24 515 M
EBIT 2017 15 036 M
Net income 2017 9 722 M
Debt 2017 4 528 M
Yield 2017 3,32%
P/E ratio 2017 8,63
P/E ratio 2018 9,53
EV / Sales 2017 3,61x
EV / Sales 2018 4,04x
Capitalization 84 036 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 78,6 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-10.19%84 101
AMGEN, INC.5.74%112 531
CELGENE CORPORATION1.35%90 349
REGENERON PHARMACEUTIC..25.68%48 999
ACTELION LTD24.49%30 824
VERTEX PHARMACEUTICALS..59.90%29 624
More Results